Cannabis Rescheduling Update: What the DEA’s Latest Move Actually Means for Your Stocks

By Sheeba M. | April 18, 2026 Cannabis Rescheduling Update: What the DEA’s Latest Move Actually Means for Your Stocks TL;DR: The DEA’s proposed rescheduling to Schedule III is real progress, but it doesn’t solve the core banking, tax, or listing problems cannabis companies face. Here’s what actually changes — and what doesn’t. After years […]

Cannabis M&A Heats Up: 3 Takeover Targets Wall Street Is Watching

By Sheeba M. | April 18, 2026 Cannabis M&A Heats Up: 3 Takeover Targets Wall Street Is Watching TL;DR: With MSO balance sheets stabilizing and institutional capital returning, a new wave of cannabis M&A is inevitable. These three mid-tier operators look like prime acquisition candidates. The cannabis sector is quietly positioning itself for its next […]

Curaleaf’s International Push: Can a US-Centric MSO Win in European Cannabis Markets?

By Sheeba M. | April 18, 2026 Curaleaf’s International Push: Can a US-Centric MSO Win in European Cannabis Markets? TL;DR: Curaleaf has been aggressively acquiring European cannabis assets — but EU cannabis markets operate under entirely different regulatory rules than US state markets. The opportunity is massive; so is the execution risk. Curaleaf Holdings (CSE: […]

Small-Cap Cannabis Operators Are Quietly Outperforming the Big MSOs — Here’s Why

By Sheeba M. | April 18, 2026 Small-Cap Cannabis Operators Are Quietly Outperforming the Big MSOs — Here’s Why TL;DR: While Curaleaf and Trulieve fight margin compression, a cohort of sub-$500M cannabis operators are posting 30%+ revenue growth with leaner cost structures. The market is starting to notice. The cannabis industry’s center of gravity may […]

📅 Yesterday's News & Older Articles →